Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXYCU for Inflammation Following Ocular Surgery for Childhood Cataract
NCT05191706Phase 4Terminated
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Aug 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of IBI-10090 in post-operative ocular inflammation, sponsored by EyePoint Pharmaceuticals. Started Jan 2022; status: terminated.
02
Drugs
IBI-10090
03
Conditions
post-operative ocular inflammation
Beyond the preview
Go deeper on NCT05191706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191706.